IGC Pharma Hits 65% Enrollment in Phase 2 CALMA Trial for Alzheimer's Agitation Treatment

IGC Pharma has reached 65% enrollment in its Phase 2 CALMA trial for Alzheimer's agitation, with 146 participants planned. The trial is evaluating IGC-AD1, a cannabinoid-based formulation designed to reduce agitation in Alzheimer's dementia. Interim analyses have shown significant reductions in agitation, and full enrollment is expected by early 2026. IGC Pharma is accelerating enrollment through a hybrid recruitment strategy combining site-driven outreach with precision digital campaigns.